KLK3 and prostate carcinoma: This family includes the most important serum tumour marker in clinical medicine for the early detection, risk stratification, clinical staging, and monitoring of prostate cancer, kallikrein 3 (KLK3), which is better known as prostate-specific antigen (PSA) (Diamandis, 1998).